PDCD1 and non-small cell lung carcinoma: Our results indicate that patients with advanced or metastatic NSCLC who received PD-1/PD-L1 inhibitors in combination with abnobaViscum® therapy experienced improved survival compared to patients receiving PD-1/PD-L1 inhibitors alone.